<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02800135</url>
  </required_header>
  <id_info>
    <org_study_id>1408024</org_study_id>
    <secondary_id>141521A-11</secondary_id>
    <secondary_id>2014-005146-22</secondary_id>
    <nct_id>NCT02800135</nct_id>
  </id_info>
  <brief_title>Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term</brief_title>
  <official_title>Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) is a common disorder and associated with high morbidity and
      mortality. However, distinguishing transient AKI from persistent AKI may help in
      individualizing treatment and limit short and long term consequences of AKI. Previous studies
      suggested usual urinary indices to perform poorly for separating transient from persistent
      AKI in an unselected population of critically ill patients. The recent KDIGO (Kidney Disease
      Improving Global Outcomes) guidelines underlined the need for additional strategies in
      estimating renal short term prognosis.

      Recently, a Furosemide stress test (FST) was validated in a cohort of unselected critically
      ill patients. This stress test performance was found to be good in predicting capacity to
      identify those patients that will progress to advanced stage AKI. Additionally, FST
      performance was higher than those of usual renal biomarker. The limited sample size of this
      preliminary study however precluded adjustment for usual confounders including oliguria.

      The primary objective of this study is to assess diagnostic performance of FST in
      differentiating transient and persistent AKI. Secondary objectives are to assess diagnostic
      performance of FST in predicting need for renal replacement therapy, and to confirm FST
      results after adjustment for confounders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with renal recovery</measure>
    <time_frame>day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>natriuresis(mmol/L)</measure>
    <time_frame>day 0 to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fractional excretion of sodium(%)</measure>
    <time_frame>day 0 to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fractional excretion of urea (%),</measure>
    <time_frame>day 0 to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>U/P urea ratio(mg.dl-1/ mg.dl-1)</measure>
    <time_frame>day 0 to day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>U/P creatinine ratio (mg.dl-1/ mg.dl-1)</measure>
    <time_frame>day 0 to day 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Critical Illness</condition>
  <condition>Oliguria</condition>
  <arm_group>
    <arm_group_label>Furosemide stress test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.</description>
    <arm_group_label>Furosemide stress test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (age &gt; 18 y.o)

          -  AKI stage 1 or more according to KDIGO

          -  Oliguria as defined by an oliguria lower than 0.5 mL/Kg

          -  Affiliation to the National Medical Insurance

        Exclusion Criteria:

          -  Pregnancy

          -  Chronic kidney disease stage 4 or more

          -  Need for fluid bolus (&gt;1000 mL crystalloids or equivalent) or need for vasopressors
             increases or introduction in the 2 hours preceding inclusion

          -  Evidence of obstructive renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael DARMON, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael DARMON, MD PhD</last_name>
    <phone>(0)477127853</phone>
    <phone_ext>+33</phone_ext>
    <email>michael.darmon@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de CLERMONT-FERRAND</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand SOUWEINE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de MONTPELLIER</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kada KLOUCHE, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>michael DARMON, MD PhD</last_name>
      <phone>(0)477127793</phone>
      <phone_ext>+33</phone_ext>
      <email>michael.darmon@chu-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carine LABRUYERE, CRA</last_name>
      <phone>(0)477120469</phone>
      <phone_ext>+33</phone_ext>
      <email>carine.labruyere@chu-st-etienne.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRU de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David SCHNELL, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Oliguria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

